Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-): clinical trial for genotypying of two metabolizing enzymes (CYP2D6 und CYP3A5*3). (Erhöhte Eliminationsraten von Quetiapin bei jugendlichen Patienten mit Schizophrenie (ICD 10: F 20.-), bipolar affektiver Störung (ICD 10: F 31.-) bzw. Störung der Impulskontrolle bei vorliegender PTBS (ICD 10: F 43.1) oder Persönlichkeitsstörung (ICD 10: F 60.-): Klinische Studie zur Genotypisierung zweier metabolisierender Enzyme (CYP2D6 und CYP3A5*3).)

Trial Profile

Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-): clinical trial for genotypying of two metabolizing enzymes (CYP2D6 und CYP3A5*3). (Erhöhte Eliminationsraten von Quetiapin bei jugendlichen Patienten mit Schizophrenie (ICD 10: F 20.-), bipolar affektiver Störung (ICD 10: F 31.-) bzw. Störung der Impulskontrolle bei vorliegender PTBS (ICD 10: F 43.1) oder Persönlichkeitsstörung (ICD 10: F 60.-): Klinische Studie zur Genotypisierung zweier metabolisierender Enzyme (CYP2D6 und CYP3A5*3).)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Midazolam (Primary) ; Quetiapine (Primary)
  • Indications Bipolar disorders; Impulse control disorders; Personality disorders; Post-traumatic stress disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Mar 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top